Company Description
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector.
The company’s lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery.
It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.
Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
| Country | Canada |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | James Helliwell |
Contact Details
Address: 2067 Cadboro Bay Road, Suite 201 Victoria, BC V8R 5G4 Canada | |
| Phone | 250 590 3968 |
| Website | eupraxiapharma.com |
Stock Details
| Ticker Symbol | EPRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001581178 |
| ISIN Number | CA29842P1053 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James A. Helliwell FRCPC, M.D. | Chief Executive Officer and Director |
| Bruce G. Cousins C.A., CPA | President and Chief Financial Officer |
| Dr. Amanda Malone Ph.D. | Chief Scientific Officer and Chief Operating Officer |
| Paul Anthony Brennan B.Sc., M.Sc. | Chief Business Officer |
| Dr. Mark M. Kowalski M.D., Ph.D. | Chief Medical Officer |
| Dr. Rahul Sarugaser M.B.A., Ph.D. | Executive Vice President of Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | 6-K | Report of foreign issuer |
| Nov 14, 2024 | 6-K | Report of foreign issuer |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 6-K | Report of foreign issuer |
| Nov 13, 2024 | 6-K | Report of foreign issuer |
| Nov 8, 2024 | D | Notice of Exempt Offering of Securities |
| Nov 7, 2024 | 6-K | Report of foreign issuer |
| Nov 7, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Nov 1, 2024 | 6-K | Report of foreign issuer |
| Oct 28, 2024 | 6-K | Report of foreign issuer |